CHARACTERIZATION OF HEPATIC UPTAKE MECHANISM FOR SN-38, AN ACTIVE METABOLITE OF THE ANTICANCER AGENT IRINOTECAN IN HUMANS

被引：0
|
作者：
Kato, Yukio [1 ]
机构：
[1] Kanazawa Univ, Kanazawa, Ishikawa 9201192, Japan
来源：
DRUG METABOLISM REVIEWS | 2012年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [1] Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes
    Haaz, MC
    Rivory, L
    Jantet, S
    Ratanasavanh, D
    Robert, J
    PHARMACOLOGY & TOXICOLOGY, 1997, 80 (02): : 91 - 96
  • [2] Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans
    Fujita, Ken-ichi
    Sugiura, Tomoko
    Okumura, Hidenori
    Umeda, Saki
    Nakamichi, Noritaka
    Watanabe, Yusuke
    Suzuki, Hiromichi
    Sunakawa, Yu
    Shimada, Ken
    Kawara, Kaori
    Sasaki, Yasutsuna
    Kato, Yukio
    PHARMACEUTICAL RESEARCH, 2014, 31 (01) : 204 - 215
  • [3] Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans
    Ken-ichi Fujita
    Tomoko Sugiura
    Hidenori Okumura
    Saki Umeda
    Noritaka Nakamichi
    Yusuke Watanabe
    Hiromichi Suzuki
    Yu Sunakawa
    Ken Shimada
    Kaori Kawara
    Yasutsuna Sasaki
    Yukio Kato
    Pharmaceutical Research, 2014, 31 : 204 - 215
  • [4] OATP1B1-MEDIATED HEPATIC UPTAKE OF SN-38, AN ACTIVE METABOLITE OF IRINOTECAN, AND ITS INHIBITION BY UREMIC TOXINS IN HUMANS
    Fujita, K.
    Sugiura, T.
    Okumura, H.
    Umeda, S.
    Nakamichi, N.
    Sasaki, Y.
    Kato, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S32 - S32
  • [5] Development of ELISAs for irinotecan and its active metabolite SN-38
    Saita, T
    Fujito, H
    Mori, M
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2000, 23 (08) : 911 - 916
  • [6] Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cells
    Kobayashi, K
    Ceryak, S
    Matsuzaki, Y
    Kudoh, S
    Bouscarel, B
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2001, 1525 (1-2): : 125 - 129
  • [7] pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells
    Kobayashi, K
    Bouscarel, B
    Matsuzaki, Y
    Ceryak, S
    Kudoh, S
    Fromm, H
    INTERNATIONAL JOURNAL OF CANCER, 1999, 83 (04) : 491 - 496
  • [8] Panipenem Does Not Alter the Pharmacokinetics of the Active Metabolite of Irinotecan SN-38 and Inactive Metabolite SN-38 Glucuronide (SN-38G) in Rats
    Kato, Ayako
    Ueyama, Jun
    Abe, Fumie
    Hotta, Kazuo
    Tsukiyama, Ikuto
    Oshima, Taeyuki
    Kondo, Fumio
    Saito, Hiroko
    Hasegawa, Takaaki
    ANTICANCER RESEARCH, 2011, 31 (09) : 2915 - 2922
  • [9] Effect of Tacrolimus on the Pharmacokinetics and Glucuronidation of SN-38, an Active Metabolite of Irinotecan
    Tanaka, Yoshiteru
    Katoh, Miki
    Fujioka, Miho
    Onishi, Katsuhiro
    Sakakibara, Yukiko
    Hasegawa, Takaaki
    Nadai, Masayuki
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2013, 133 (04): : 463 - 471
  • [10] Passage of irinotecan and its active metabolite, SN-38, into human milk
    Nakagawa, J.
    Terui, K.
    Hosoi, K.
    Ueno, K.
    Yokoyama, Y.
    Hayakari, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (05) : 579 - 582
12345